Figure 2.

Visual scores, dialyzer circuit change outs, saline flush events, and blood clot markers in the treatment arms. (A) The percent of severe clotting events (as defined as a visual score of ≥3) in each group (placebo, red bars; 0.25 mg/kg, blue bars; and 0.5 mg/kg, light green bars) within the hemodialysis cartridge. Predose data combine all predose hemodialysis days (study days −7, −5, and −3). (B) The bars represent the percent of occlusive events requiring change out of the hemodialysis circuit postdose (study days 1, 3, and 5 combined) compared with predose (study days −7, −5, and −3 combined). (C) Likewise, the bars represent the percent of hemodialysis circuit saline flushes required to maintain circuit patency postdose (study days 1, 3, and 5 combined) compared with predose (study days −7, −5, and −3 combined). (D-E) AB023 significantly reduces blood clot markers within the hemodialysis cartridge. AB023 (0.5 mg/kg) significantly reduced potassium (D) and iron (E) retained within the hemodialysis cartridge due to blood clotting on study day 1 compared with placebo. (F) AB023 may limit systemic increases in TAT after hemodialysis sessions. Predose samples were averaged, and shown is the percentage of predose potassium, iron, and TAT concentrations. n = 8 for placebo, n = 7 for 0.25 mg/kg, and 0.5 mg/kg potassium and iron groups (dialyzers were damaged upon receipt). Data represent mean ± SEM. *P < .05.